Mikart Announces Compliance with DSCSA Serialization Requirement

News
Article

The company announced that it is fully compliant with the 2017–2023 serialization and aggregation requirements.

On June 5, 2017, Mikart announced that it is fully compliant with 2017–2023 serialization and aggregation requirements in the Drug Supply Chain Security Act. The Atlanta-based company has partnered with Optel Vision, which makes hardware and software that generates, reads, applies, and verifies codes throughout the entire packaging process, and TraceLink, the data warehouse that makes information contained in the serialization codes available to every point in the pharmaceutical supply chain.

Mikart offers a full range of services in addition to serialization and aggregation, including pharmaceutical development, clinical trial manufacturing and packaging, regulatory submissions, commercial scale manufacturing, and packaging solutions.

Source: Mikart 

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Related Content